Topics:
Gynecologic Cancers • Endometrial Cancer
Would you incorporate a PARP inhibitor into the management of a patient with endometrial cancer with a germline or somatic BRCA mutation?
Would you consider utilizing both immunotherapy and a PARP inhibitor in a patient with both MMR deficiency and BRCA mutation?